Ipsen (FR:IPN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ipsen has secured exclusive global rights to BMX-502, a promising preclinical T-cell engager developed by Biomunex, aiming to harness MAIT cells for cancer treatment. This innovative bispecific antibody targets MAIT cells and the tumor antigen GPC3, potentially offering a more effective and safer therapy for solid tumors. Ipsen will handle clinical development and commercialization, while Biomunex stands to receive up to $610 million through various payments and royalties.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.